Immunoregulatory mechanisms of macrophage PPAR-γ in mice with experimental inflammatory bowel disease.
Identifieur interne : 000047 ( PubMed/Corpus ); précédent : 000046; suivant : 000048Immunoregulatory mechanisms of macrophage PPAR-γ in mice with experimental inflammatory bowel disease.
Auteurs : R. Hontecillas ; W T Horne ; M. Climent ; A J Guri ; C. Evans ; Y. Zhang ; B W Sobral ; J. Bassaganya-RieraSource :
- Mucosal immunology [ 1935-3456 ] ; 2011.
English descriptors
- KwdEn :
- Animals, Anti-Inflammatory Agents (pharmacology), Anti-Inflammatory Agents (therapeutic use), Cells, Cultured, Colitis (chemically induced), Colitis (drug therapy), Colitis (immunology), Colon (pathology), Computational Biology, Dextran Sulfate (administration & dosage), Disease Models, Animal, Gene Expression Regulation (immunology), Humans, Immunomodulation, Inflammatory Bowel Diseases (drug therapy), Inflammatory Bowel Diseases (immunology), Macrophages (drug effects), Macrophages (immunology), Macrophages (metabolism), Macrophages (pathology), Mice, Mice, Inbred C57BL, Mice, Mutant Strains, Microarray Analysis, Mucous Membrane (pathology), PPAR gamma (antagonists & inhibitors), PPAR gamma (genetics), PPAR gamma (immunology), PPAR gamma (metabolism), T-Lymphocyte Subsets (drug effects), T-Lymphocyte Subsets (immunology), T-Lymphocyte Subsets (metabolism), T-Lymphocyte Subsets (pathology), T-Lymphocytes, Regulatory (drug effects), T-Lymphocytes, Regulatory (immunology), T-Lymphocytes, Regulatory (metabolism), T-Lymphocytes, Regulatory (pathology), Thiazolidinediones (pharmacology), Thiazolidinediones (therapeutic use).
- MESH :
- chemical , administration & dosage : Dextran Sulfate.
- chemical , antagonists & inhibitors : PPAR gamma.
- chemical , genetics : PPAR gamma.
- chemical , immunology : PPAR gamma.
- chemical , metabolism : PPAR gamma.
- chemical , pharmacology : Anti-Inflammatory Agents, Thiazolidinediones.
- chemical , therapeutic use : Anti-Inflammatory Agents, Thiazolidinediones.
- chemically induced : Colitis.
- drug effects : Macrophages, T-Lymphocyte Subsets, T-Lymphocytes, Regulatory.
- drug therapy : Colitis, Inflammatory Bowel Diseases.
- immunology : Colitis, Gene Expression Regulation, Inflammatory Bowel Diseases, Macrophages, T-Lymphocyte Subsets, T-Lymphocytes, Regulatory.
- metabolism : Macrophages, T-Lymphocyte Subsets, T-Lymphocytes, Regulatory.
- pathology : Colon, Macrophages, Mucous Membrane, T-Lymphocyte Subsets, T-Lymphocytes, Regulatory.
- Animals, Cells, Cultured, Computational Biology, Disease Models, Animal, Humans, Immunomodulation, Mice, Mice, Inbred C57BL, Mice, Mutant Strains, Microarray Analysis.
Abstract
Peroxisome proliferator-activated receptor-γ (PPAR-γ) is widely expressed in macrophages and has been identified as a putative target for the development of novel therapies against inflammatory bowel disease (IBD). Computational simulations identified macrophages as key targets for therapeutic interventions against IBD. This study aimed to characterize the mechanisms underlying the beneficial effects of macrophage PPAR-γ in IBD. Macrophage-specific PPAR-γ deletion significantly exacerbated clinical activity and colonic pathology, impaired the splenic and mesenteric lymph node regulatory T-cell compartment, increased percentages of lamina propria (LP) CD8+ T cells, increased surface expression of CD40, Ly6C, and Toll-like receptor 4 (TLR-4) in LP macrophages, and upregulated expression of colonic IFN-γ, CXCL9, CXCL10, IL-22, IL1RL1, CCR1, suppressor of cytokine signaling 3, and MHC class II in mice with IBD. Moreover, macrophage PPAR-γ was required for accelerating pioglitazone-mediated recovery from dextran sodium sulfate (DSS) colitis, providing a cellular target for the anti-inflammatory effects of PPAR-γ agonists in IBD.
DOI: 10.1038/mi.2010.75
PubMed: 21068720
Links to Exploration step
pubmed:21068720Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Immunoregulatory mechanisms of macrophage PPAR-γ in mice with experimental inflammatory bowel disease.</title><author><name sortKey="Hontecillas, R" sort="Hontecillas, R" uniqKey="Hontecillas R" first="R" last="Hontecillas">R. Hontecillas</name><affiliation><nlm:affiliation>CyberInfrastructure Division, Virginia Bioinformatics Institute, Virginia Polytechnic Institute and State University, Blacksburg, Virginia, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Horne, W T" sort="Horne, W T" uniqKey="Horne W" first="W T" last="Horne">W T Horne</name></author><author><name sortKey="Climent, M" sort="Climent, M" uniqKey="Climent M" first="M" last="Climent">M. Climent</name></author><author><name sortKey="Guri, A J" sort="Guri, A J" uniqKey="Guri A" first="A J" last="Guri">A J Guri</name></author><author><name sortKey="Evans, C" sort="Evans, C" uniqKey="Evans C" first="C" last="Evans">C. Evans</name></author><author><name sortKey="Zhang, Y" sort="Zhang, Y" uniqKey="Zhang Y" first="Y" last="Zhang">Y. Zhang</name></author><author><name sortKey="Sobral, B W" sort="Sobral, B W" uniqKey="Sobral B" first="B W" last="Sobral">B W Sobral</name></author><author><name sortKey="Bassaganya Riera, J" sort="Bassaganya Riera, J" uniqKey="Bassaganya Riera J" first="J" last="Bassaganya-Riera">J. Bassaganya-Riera</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2011">2011</date><idno type="doi">10.1038/mi.2010.75</idno><idno type="RBID">pubmed:21068720</idno><idno type="pmid">21068720</idno><idno type="wicri:Area/PubMed/Corpus">000047</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Immunoregulatory mechanisms of macrophage PPAR-γ in mice with experimental inflammatory bowel disease.</title><author><name sortKey="Hontecillas, R" sort="Hontecillas, R" uniqKey="Hontecillas R" first="R" last="Hontecillas">R. Hontecillas</name><affiliation><nlm:affiliation>CyberInfrastructure Division, Virginia Bioinformatics Institute, Virginia Polytechnic Institute and State University, Blacksburg, Virginia, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Horne, W T" sort="Horne, W T" uniqKey="Horne W" first="W T" last="Horne">W T Horne</name></author><author><name sortKey="Climent, M" sort="Climent, M" uniqKey="Climent M" first="M" last="Climent">M. Climent</name></author><author><name sortKey="Guri, A J" sort="Guri, A J" uniqKey="Guri A" first="A J" last="Guri">A J Guri</name></author><author><name sortKey="Evans, C" sort="Evans, C" uniqKey="Evans C" first="C" last="Evans">C. Evans</name></author><author><name sortKey="Zhang, Y" sort="Zhang, Y" uniqKey="Zhang Y" first="Y" last="Zhang">Y. Zhang</name></author><author><name sortKey="Sobral, B W" sort="Sobral, B W" uniqKey="Sobral B" first="B W" last="Sobral">B W Sobral</name></author><author><name sortKey="Bassaganya Riera, J" sort="Bassaganya Riera, J" uniqKey="Bassaganya Riera J" first="J" last="Bassaganya-Riera">J. Bassaganya-Riera</name></author></analytic><series><title level="j">Mucosal immunology</title><idno type="eISSN">1935-3456</idno><imprint><date when="2011" type="published">2011</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Anti-Inflammatory Agents (pharmacology)</term><term>Anti-Inflammatory Agents (therapeutic use)</term><term>Cells, Cultured</term><term>Colitis (chemically induced)</term><term>Colitis (drug therapy)</term><term>Colitis (immunology)</term><term>Colon (pathology)</term><term>Computational Biology</term><term>Dextran Sulfate (administration & dosage)</term><term>Disease Models, Animal</term><term>Gene Expression Regulation (immunology)</term><term>Humans</term><term>Immunomodulation</term><term>Inflammatory Bowel Diseases (drug therapy)</term><term>Inflammatory Bowel Diseases (immunology)</term><term>Macrophages (drug effects)</term><term>Macrophages (immunology)</term><term>Macrophages (metabolism)</term><term>Macrophages (pathology)</term><term>Mice</term><term>Mice, Inbred C57BL</term><term>Mice, Mutant Strains</term><term>Microarray Analysis</term><term>Mucous Membrane (pathology)</term><term>PPAR gamma (antagonists & inhibitors)</term><term>PPAR gamma (genetics)</term><term>PPAR gamma (immunology)</term><term>PPAR gamma (metabolism)</term><term>T-Lymphocyte Subsets (drug effects)</term><term>T-Lymphocyte Subsets (immunology)</term><term>T-Lymphocyte Subsets (metabolism)</term><term>T-Lymphocyte Subsets (pathology)</term><term>T-Lymphocytes, Regulatory (drug effects)</term><term>T-Lymphocytes, Regulatory (immunology)</term><term>T-Lymphocytes, Regulatory (metabolism)</term><term>T-Lymphocytes, Regulatory (pathology)</term><term>Thiazolidinediones (pharmacology)</term><term>Thiazolidinediones (therapeutic use)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Dextran Sulfate</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>PPAR gamma</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>PPAR gamma</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>PPAR gamma</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>PPAR gamma</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Anti-Inflammatory Agents</term><term>Thiazolidinediones</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Inflammatory Agents</term><term>Thiazolidinediones</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Colitis</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Macrophages</term><term>T-Lymphocyte Subsets</term><term>T-Lymphocytes, Regulatory</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Colitis</term><term>Inflammatory Bowel Diseases</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Colitis</term><term>Gene Expression Regulation</term><term>Inflammatory Bowel Diseases</term><term>Macrophages</term><term>T-Lymphocyte Subsets</term><term>T-Lymphocytes, Regulatory</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Macrophages</term><term>T-Lymphocyte Subsets</term><term>T-Lymphocytes, Regulatory</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Colon</term><term>Macrophages</term><term>Mucous Membrane</term><term>T-Lymphocyte Subsets</term><term>T-Lymphocytes, Regulatory</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Cells, Cultured</term><term>Computational Biology</term><term>Disease Models, Animal</term><term>Humans</term><term>Immunomodulation</term><term>Mice</term><term>Mice, Inbred C57BL</term><term>Mice, Mutant Strains</term><term>Microarray Analysis</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Peroxisome proliferator-activated receptor-γ (PPAR-γ) is widely expressed in macrophages and has been identified as a putative target for the development of novel therapies against inflammatory bowel disease (IBD). Computational simulations identified macrophages as key targets for therapeutic interventions against IBD. This study aimed to characterize the mechanisms underlying the beneficial effects of macrophage PPAR-γ in IBD. Macrophage-specific PPAR-γ deletion significantly exacerbated clinical activity and colonic pathology, impaired the splenic and mesenteric lymph node regulatory T-cell compartment, increased percentages of lamina propria (LP) CD8+ T cells, increased surface expression of CD40, Ly6C, and Toll-like receptor 4 (TLR-4) in LP macrophages, and upregulated expression of colonic IFN-γ, CXCL9, CXCL10, IL-22, IL1RL1, CCR1, suppressor of cytokine signaling 3, and MHC class II in mice with IBD. Moreover, macrophage PPAR-γ was required for accelerating pioglitazone-mediated recovery from dextran sodium sulfate (DSS) colitis, providing a cellular target for the anti-inflammatory effects of PPAR-γ agonists in IBD.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">21068720</PMID><DateCreated><Year>2011</Year><Month>04</Month><Day>19</Day></DateCreated><DateCompleted><Year>2011</Year><Month>08</Month><Day>17</Day></DateCompleted><DateRevised><Year>2015</Year><Month>08</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1935-3456</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>3</Issue><PubDate><Year>2011</Year><Month>May</Month></PubDate></JournalIssue><Title>Mucosal immunology</Title><ISOAbbreviation>Mucosal Immunol</ISOAbbreviation></Journal><ArticleTitle>Immunoregulatory mechanisms of macrophage PPAR-γ in mice with experimental inflammatory bowel disease.</ArticleTitle><Pagination><MedlinePgn>304-13</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/mi.2010.75</ELocationID><Abstract><AbstractText>Peroxisome proliferator-activated receptor-γ (PPAR-γ) is widely expressed in macrophages and has been identified as a putative target for the development of novel therapies against inflammatory bowel disease (IBD). Computational simulations identified macrophages as key targets for therapeutic interventions against IBD. This study aimed to characterize the mechanisms underlying the beneficial effects of macrophage PPAR-γ in IBD. Macrophage-specific PPAR-γ deletion significantly exacerbated clinical activity and colonic pathology, impaired the splenic and mesenteric lymph node regulatory T-cell compartment, increased percentages of lamina propria (LP) CD8+ T cells, increased surface expression of CD40, Ly6C, and Toll-like receptor 4 (TLR-4) in LP macrophages, and upregulated expression of colonic IFN-γ, CXCL9, CXCL10, IL-22, IL1RL1, CCR1, suppressor of cytokine signaling 3, and MHC class II in mice with IBD. Moreover, macrophage PPAR-γ was required for accelerating pioglitazone-mediated recovery from dextran sodium sulfate (DSS) colitis, providing a cellular target for the anti-inflammatory effects of PPAR-γ agonists in IBD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hontecillas</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>CyberInfrastructure Division, Virginia Bioinformatics Institute, Virginia Polytechnic Institute and State University, Blacksburg, Virginia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horne</LastName><ForeName>W T</ForeName><Initials>WT</Initials></Author><Author ValidYN="Y"><LastName>Climent</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Guri</LastName><ForeName>A J</ForeName><Initials>AJ</Initials></Author><Author ValidYN="Y"><LastName>Evans</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Sobral</LastName><ForeName>B W</ForeName><Initials>BW</Initials></Author><Author ValidYN="Y"><LastName>Bassaganya-Riera</LastName><ForeName>J</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>5R01AT004308</GrantID><Acronym>AT</Acronym><Agency>NCCIH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AT004308</GrantID><Acronym>AT</Acronym><Agency>NCCIH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AT004308-03</GrantID><Acronym>AT</Acronym><Agency>NCCIH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>11</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mucosal Immunol</MedlineTA><NlmUniqueID>101299742</NlmUniqueID><ISSNLinking>1933-0219</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047495">PPAR gamma</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D045162">Thiazolidinediones</NameOfSubstance></Chemical><Chemical><RegistryNumber>9042-14-2</RegistryNumber><NameOfSubstance UI="D016264">Dextran Sulfate</NameOfSubstance></Chemical><Chemical><RegistryNumber>X4OV71U42S</RegistryNumber><NameOfSubstance UI="C060836">pioglitazone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>J Nutr. 2010 Mar;140(3):515-21</RefSource><PMID Version="1">20089779</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Inflamm Bowel Dis. 2006 Nov;12(11):1013-24</RefSource><PMID Version="1">17075342</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2010;5(4):e10215</RefSource><PMID Version="1">20422041</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Theor Biol. 2010 Jun 21;264(4):1225-39</RefSource><PMID Version="1">20362587</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>BMC Gastroenterol. 2010;10:60</RefSource><PMID Version="1">20537136</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Curr Opin Clin Nutr Metab Care. 2010 Sep;13(5):569-73</RefSource><PMID Version="1">20508519</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Nutr. 2010 Dec;29(6):824-31</RefSource><PMID Version="1">20236740</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Nutr Biochem. 2011 Sep;22(9):812-9</RefSource><PMID Version="1">21109419</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Gastroenterol. 1999 Nov;94(11):3279-84</RefSource><PMID Version="1">10566730</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Gastroenterol. 2001 Dec;96(12):3323-8</RefSource><PMID Version="1">11774944</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Gastroenterol Hepatol. 2002 Mar;14(3):237-41</RefSource><PMID Version="1">11953687</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Nutr. 2002 Jul;132(7):2019-27</RefSource><PMID Version="1">12097686</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Gastroenterology. 2003 May;124(5):1265-76</RefSource><PMID Version="1">12730867</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Rev Gastroenterol Disord. 2003 Spring;3(2):81-92</RefSource><PMID Version="1">12776005</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Nutr. 2003 Oct;133(10):3204-14</RefSource><PMID Version="1">14519812</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Bioinformatics. 2004 Feb 12;20(3):307-15</RefSource><PMID Version="1">14960456</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Pharmacother. 2004 Sep;38(9):1419-23</RefSource><PMID Version="1">15266041</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Gastroenterology. 2004 Sep;127(3):777-91</RefSource><PMID Version="1">15362034</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Genome Biol. 2004;5(10):R80</RefSource><PMID Version="1">15461798</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Science. 1994 Nov 18;266(5188):1253-5</RefSource><PMID Version="1">7973709</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 1998 Jan 1;391(6662):79-82</RefSource><PMID Version="1">9422508</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Physiol Gastrointest Liver Physiol. 2007 Feb;292(2):G657-66</RefSource><PMID Version="1">17095756</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Immunol. 2007 Mar 1;178(5):2940-9</RefSource><PMID Version="1">17312139</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Gastroenterology. 2007 Mar;132(3):955-65</RefSource><PMID Version="1">17324402</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 2007 Jun 28;447(7148):1116-20</RefSource><PMID Version="1">17515919</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Gastroenterology. 2008 Mar;134(3):688-95</RefSource><PMID Version="1">18325386</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Hum Gene Ther. 2008 Mar;19(3):287-299</RefSource><PMID Version="1">18302511</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Dev Neurosci. 2008 Aug;26(5):505-15</RefSource><PMID Version="1">18455351</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Immunol. 2009 Jan;39(1):26-35</RefSource><PMID Version="1">19137537</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cell Immunol. 2009;258(2):138-46</RefSource><PMID Version="1">19423085</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7614-9</RefSource><PMID Version="1">9636198</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Immunol. 1999 Oct 1;163(7):4049-57</RefSource><PMID Version="1">10491009</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Endocr Rev. 1999 Oct;20(5):649-88</RefSource><PMID Version="1">10529898</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cytokine. 2005 May 21;30(4):168-76</RefSource><PMID Version="1">15863390</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 2005 Sep 29;437(7059):759-63</RefSource><PMID Version="1">16127449</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cell Microbiol. 2006 Mar;8(3):401-13</RefSource><PMID Version="1">16469053</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Nutr. 2006 Jun;25(3):454-65</RefSource><PMID Version="1">16698153</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Gut. 2006 Aug;55(8):1104-13</RefSource><PMID Version="1">16547072</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Nephrol. 2006;26(4):356-62</RefSource><PMID Version="1">16864989</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Pathol. 2010 Apr;176(4):1816-27</RefSource><PMID Version="1">20133813</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000893">Anti-Inflammatory Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002478">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003092">Colitis</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003106">Colon</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D019295">Computational Biology</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016264">Dextran Sulfate</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004195">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005786">Gene Expression Regulation</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D056747">Immunomodulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015212">Inflammatory Bowel Diseases</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008264">Macrophages</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008817">Mice, Mutant Strains</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D046228">Microarray Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009092">Mucous Membrane</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D047495">PPAR gamma</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000037">antagonists & inhibitors</QualifierName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016176">T-Lymphocyte Subsets</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D050378">T-Lymphocytes, Regulatory</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D045162">Thiazolidinediones</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><OtherID Source="NLM">NIHMS253584</OtherID><OtherID Source="NLM">PMC3049196</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="aheadofprint"><Year>2010</Year><Month>11</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>11</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>11</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>8</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pii">mi201075</ArticleId><ArticleId IdType="doi">10.1038/mi.2010.75</ArticleId><ArticleId IdType="pubmed">21068720</ArticleId><ArticleId IdType="pmc">PMC3049196</ArticleId><ArticleId IdType="mid">NIHMS253584</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Ticri/CIDE/explor/CyberinfraV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000047 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000047 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Ticri/CIDE
|area= CyberinfraV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:21068720
|texte= Immunoregulatory mechanisms of macrophage PPAR-γ in mice with experimental inflammatory bowel disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:21068720" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CyberinfraV1
| This area was generated with Dilib version V0.6.25. |  |